Please note that the ANZCTR website will be unavailable from 1pm until 2pm (AEST) on Wednesday 29th May for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617001640392
Ethics application status
Approved
Date submitted
4/10/2017
Date registered
18/12/2017
Date last updated
18/12/2017
Type of registration
Retrospectively registered

Titles & IDs
Public title
A Phase 1, Open-Label, Randomised, Two-Way Crossover Study to Assess the Pharmacokinetics, Relative Bioavailability and Food-Effect of a Single Dose of an Immediate Release and Extended Release Formulation of Propagermanium in Healthy Volunteers
Scientific title
A Phase 1, Open-Label, Randomised, Two-Way Crossover Study to Assess the Pharmacokinetics, Relative Bioavailability and Food-Effect of a Single Dose of an Immediate Release and Extended Release Formulation of Propagermanium in Healthy Volunteers
Secondary ID [1] 293001 0
DMX-200-101
Universal Trial Number (UTN)
U1111-1202-9051
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
proteinuria 304914 0
chronic kidney disease 305300 0
Condition category
Condition code
Renal and Urogenital 304245 304245 0 0
Kidney disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Phase 1 study in healthy volunteers involving 2 Cohorts (Cohort A and Cohort B).
propagermanium:
Extended Release tablets of 120 mg propagermanium (4 x 30 mg tablets) for oral administration. Single dose administration over three treatment periods.
Participants in Cohort A will receive the immediate release (IR) formulation while fasting at Dose 1, the extended release (ER) formulation while fasting at Dose 2, and the ER formulation after a meal at Dose 3. Participants in Cohort B will receive the ER formulation while fasting at Dose 1, the IR formulation while fasting at Dose 2, and the ER formulation after a meal at Dose 3.
Participants will not have a choice as to which cohort they are assigned (randomised) to and the ratio is 1:1 for each cohort. The IP will be administered with 250 mL water.
All participants from both cohorts will receive study drug on Day 1 (Dose 1), Day 8 (Dose 2) and Day 15 (Dose 3), as such there will be a 7 day wash out period between treatments.
Intervention code [1] 299245 0
Treatment: Drugs
Comparator / control treatment
Active control treatment: Immediate Release (IR) capsules of 120 mg propagermanium (4 x 30 mg capsules) for single oral dose administration.
Control group
Active

Outcomes
Primary outcome [1] 303531 0
Assessment of PK parameters of propagermanium in plasma.
Plasma PK parameters: Cmax, tmax, tlag, AUC0-last, kel, AUC8, t1/2, CL/F, Vz/F
Timepoint [1] 303531 0
Plasma PK sampling schedule:
Day 1 – pre-dose (with 15 mins prior), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 18 hours post dose 1
Day 2 – 24 and 30 hours post dose 1
Day 8 – pre-dose (with 15 mins prior), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18 hours post dose 2
Day 9 – 24 and 30 hours post dose 2
Day 15 – pre-dose (with 15 mins prior), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18 hours post dose 3
Day 16 – 24 and 30 hours post dose 3
The allowed time deviation window for blood sample collection is ± 5 minutes for the samples up to 2 hours, and ± 10 minutes at time points up to 30 hours before a deviation is recorded
Primary outcome [2] 303886 0
Assessment of the excretion of propagermanium in urine.
Urine PK parameters: Ae, FEgermanium, CLr
Timepoint [2] 303886 0
Urine PK sampling schedule:
Pre-dose (emptying the bladder), then 0-4, 4-8, 8-12, 12-18, 18-24 and 24-30 hours after dosing
Primary outcome [3] 303887 0
Assessment of the relative bioavailability of extended release propagermanium between
fasting and fed using Frel=(AUCER(fed)/AUCER(fast))
Timepoint [3] 303887 0
Plasma PK sampling schedule to assess bioavailability:
Day 1 – pre-dose (with 15 mins prior), 2, 3, 4, 5 and 6 hours post dose 1
Day 2 - 24 and 30 hours post dose 1
Day 8 – pre-dose (with 15 mins prior), 2, 3, 4, 5 and 6 hours post dose 2
Day 9 - 24 and 30 hours post dose 2
Day 15 – pre-dose (with 15 mins prior), 2, 3, 4, 5 and 6 hours post dose 3
Day 16 – 24 and 30 hours post dose 3
The allowed time deviation window for blood sample collection is ± 5 minutes for the samples up to 2 hours, and ± 10 minutes at time points up to 30 hours before a deviation is recorded
Secondary outcome [1] 339211 0
Assessment of safety.
Timepoint [1] 339211 0
Vital signs - Body temperature, blood pressure, heart rate, and respiratory rate will be evaluated.. Conducted at Screening, admission, baseline, treatment days 1, 2, 8, 9, 15, 16 and EOS (Day 24)

Clinical laboratory tests:
Biochemistry
• Blood Urea Nitrogen (BUN)
• Creatinine (CREAT)
• Total Bilirubin (BILI)
• Urate (URATE)
• Albumin (ALB)
• Alkaline Phosphatase (ALP)
• Creatine Kinase (CK)
• Aspartate Aminotransferase (AST)
• Alanine Aminotransferase (ALT)
• Glucose (GLUC)
• Sodium (SODIUM)
• Potassium (K)
• Calcium (CA)
• Chloride (CL)
• Bicarbonate (BICARB)
• Total Protein (PROT)
• Lactate Dehydrogenase (LDH)
• g-Glutamyl transferase (GGT)
• Phosphate
• Magnesium
• eGFR
Haematology
• Haemoglobin (HGB)
• Haematocrit (HCT)
• Erythrocytes (RBC)
• Platelets (PLAT)
• Leukocytes (WBC) with differential (including Eosinophils (EOS), Neutrophils
(NEUT), Basophils (BASO), Lymphocytes (LYM) and Monocytes (MONO)
• Mean cell volume
Urinalysis:
• pH (PH)
• Specific Gravity (SPGRAV)
• Protein (PROT)
• Glucose (GLUC)
• Occult Blood (OCCBLD)
• Nitrite (NITRITE)
• Leukocytes (WBC)
Conducted at Screening, admission, treatments days 2, 9, 16 and EOS (Day 24)

Physical examination:
Physical examination includes - general appearance, head, ears, eyes, nose,
throat, dentition, thyroid, chest [heart, lungs], abdomen, skin, neurological, extremities, back, neck, musculoskeletal, and lymph nodes.
Conducted at Screening, admission, treatments days 2, 9, 16 and EOS (Day 24)

Adverse events (AEs)
The most frequently reported adverse events for Serocion® (marketed name for propagermanium) include (all occurring in <2% of the 2,015 patients studied):
• Elevated AST – assessed as part of safety labs
• Elevated ALT – assessed as part of safety labs
• Malaise – reported during AE assessment
• Loss of appetite (18 patients) - reported during AE assessment
Conducted at Screening
Admission
Day 1 - 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18 hours post dose
Day 2 - 24 and 30 hours post dose
Day 8 - 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18 hours post dose
Day 9- 24 and 30 hours post dose
Day 15 - 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18 hours post dose
Day 16- 24 and 30 hours post dose
EOS (day 24)

12-lead electrocardiogram. All ECG tracings and QTc intervals will be reviewed.
Conducted at Screening
Admission
Day 1 - 3 and 5 hours post dose
Day 2 - 30 hours post dose
Day 8 - 3 and 5 hours post dose
Day 9 - 30 hours post dose
Day 15 - 3 and 5 hours post dose
Day 16 - 30 hours post dose
EOS (Day 24)
Secondary outcome [2] 340448 0
ADDITIONAL PRIMARY OUTCOME - assessment of the relative bioavailability (Frel) of propagermanium between IR and ER formulations using Frel=(AUCER/AUCIR)
Timepoint [2] 340448 0
Plasma PK sampling schedule to assess bioavailability:
Day 1 – pre-dose (with 15 mins prior), 2, 3, 4, 5 and 6 hours post dose 1
Day 2 - 24 and 30 hours post dose 1
Day 8 – pre-dose (with 15 mins prior), 2, 3, 4, 5 and 6 hours post dose 2
Day 9 - 24 and 30 hours post dose 2
Day 15 – pre-dose (with 15 mins prior), 2, 3, 4, 5 and 6 hours post dose 3
Day 16 – 24 and 30 hours post dose 3
The allowed time deviation window for blood sample collection is ± 5 minutes for the samples up to 2 hours, and ± 10 minutes at time points up to 30 hours before a deviation is recorded

Eligibility
Key inclusion criteria
1. Healthy male and female volunteers aged between 18 to 50 years old, inclusive, with a body mass index (BMI) between 18.0 and 30.0 kg/m2, who are non-smokers or smoking less than 10 cigarettes/day.
2. Female subjects of childbearing potential must agree to practice true abstinence (when this is in line with their preferred and usual lifestyle) or to use 2 methods of highly effective contraception during the study and for 30 days after the last dose of investigational product, and must have a negative pregnancy test at screening and prior to study drug administration.
3. Male subjects and their partners must agree to use two forms of highly effective methods of contraception during the study and for 90 days after study completion, or agree to remain abstinent during the study and for 90 days after study completion.
4. Able and willing to return to the clinic for all study procedures.
5. Able and willing to provide informed consent.
Minimum age
18 Years
Maximum age
50 Years
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Pregnant and breast-feeding women.
2. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatment; or interfering with the interpretation of data.
3. Abnormal blood pressure as determined by the Investigator.
4. Symptomatic herpes zoster within 3 months prior to screening.
5. Known history of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posterior anterior and lateral), or blood testing.
6. Lymphoma, leukaemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
7. Breast cancer within the past 10 years.
8. Alanine transaminase (ALT) >1.5x upper limit of normal (ULN).
9. Bilirubin >1.5xULN (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
10. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
11. Use of over-the-counter or prescription medication including herbal medications (with the exception of hormonal contraception for female participants) within 7 days prior to dosing or during the study period (with the exception of paracetamol).
12. Live vaccine(s) within 1 month prior to screening, or plans to receive any vaccine during the study.
13. Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to
dosing.
14. Positive hepatitis C antibody test result at screening or within 3 months prior to starting study treatment. NOTE: Participants with positive Hepatitis C antibody due to prior resolved
disease can be enrolled if a confirmatory negative Hepatitis C ribonucleic acid (RNA) test is
obtained.
15. Positive human immunodeficiency virus (HIV) antibody test.
16. Participation in any clinical study with an experimental medication or device within 30 days or 5 half-lives (whichever is longer) of enrolment.
17. Alcohol consumption greater than 28 standard drinks per week or substance abuse likely to impact protocol compliance or data quality as assessed by the Principal Investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint(s)
Pharmacokinetics / pharmacodynamics
Statistical methods / analysis
The sample size for this study is approximately 14 participants. The study is not intended to show statistical differences between treatment groups.
Safety Analysis Set: All participants who receive any amount of study drug (propagermanium).
PK Analysis Set: All participants who receive study drug (propagermanium) and have sufficient PK data for analysis.
PD Analysis Set: All participants who received any amount of study drug (propagermanium) and who have results from baseline and from greater or equal to 1 post-baseline Pharmacodynamic (PD) assessment.
Frequencies and percentages will be presented for the categorical variable and descriptive statistics (arithmetic mean, standard deviation [SD], median, minimum and maximum) will be presented for continuous variables. Summary results will be presented by treatment (i.e., IR vs ER) and by meal status (i.e. fed vs fasted).
Safety and Tolerability:
Adverse events (AEs) will be coded using the most current Medical Dictionary for Regulatory Activities (MedDRA (Registered Trademark) available at CNS. A by-participant AE data listing, including verbatim term, preferred term, system organ class, treatment, severity, and relationship to study drug, will be provided. The number of participants experiencing treatment emergent AEs (TEAE) and number of individual TEAE will be summarized by treatment group/meal status, system organ class and preferred term. TEAEs will also be summarized by severity and by relationship to study drug.
Laboratory evaluations, vital signs assessments and ECG parameters will be listed for each participant and summarized by treatment group/meal status and protocol specified collection time-point. A summary of change from baseline at each protocol specified time-point will also be presented. Individual time course profiles will be presented for participants with clinical laboratory results deemed clinically significant.
Changes in physical examination will be listed for each participant and described in the text of the final report.
Concomitant medications will be listed by participant and coded using the most current World Health Organization (WHO) drug dictionary available at CNS.
Medical history will be listed by participant.
Pharmacokinetics:
Individual propagermanium concentration data will be listed and summarised by treatment group with descriptive statistics sample size [N], arithmetic mean, SD, median, minimum, maximum and geometric mean). Individual and mean propagermanium concentration-time profiles for each treatment group/meal status will also be presented graphically.
Plasma propagermanium parameters will be determined using a non-compartmental analysis (NCA) approach.
The plasma PK parameters time to maximum observed drug concentration (tmax), maximum observed drug concentration (Cmax), lag time (tlag), area under the curve (AUC) from time zero to last measurable concentration (AUC0-last), AUC from time zero to infinity (AUC8), apparent elimination half-life, apparent terminal elimination rate constant (Kel), apparent clearance (CL/F) and apparent volume of distribution at the terminal phase (Vz/F) (where data are sufficient for parameter determination) will be determined.
The urine PK parameters amount excreted (Ae), fraction of dose excreted (FEgermanium) and renal clearance (CLr) will be determined
Pharmacokinetic parameters will be listed for each participant and summarized by treatment group/meal status using descriptive statistics (N, arithmetic mean, SD, coefficient of variation [CV%], median, minimum, maximum, geometric mean and geometric CV%).
Relative bioavailability of propagermanium will be assessed by estimating the 90% confidence interval (CI) for the ratio of ER vs IR geometric means for the PK parameters AUC0-last and AUC8.
Assessment of a potential food effect will be determined by estimating the 90% Confidence Interval (CI) for the ratio of fed verses fasted geometric means for the PK parameters AUC0-last, AUC8, and Cmax conditions.
Exploratory assessment of CCL2 and plasma and urine inflammatory biomarkers will also be conducted. No formal comparison of biomarkers will be conducted between groups or fed-fasting state.
Additional statistical analysis will be performed if deemed appropriate.

The assessment of biomarkers is an exploratory outcome only.

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 9123 0
Linear Clinical Research - Nedlands
Recruitment postcode(s) [1] 17629 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 297635 0
Commercial sector/Industry
Name [1] 297635 0
Dimerix Bioscience Pty Ltd
Address [1] 297635 0
Level 11, 63 Exhibition Street
Melbourne VIC 3000
Country [1] 297635 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Clinical Network Services Pty Ltd
Address
Level 4,
88 Jephson Street
Toowong
QLD 4066
Country
Australia
Secondary sponsor category [1] 296654 0
None
Name [1] 296654 0
Address [1] 296654 0
Country [1] 296654 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 298722 0
Bellberry Human Research Ethics Committee
Ethics committee address [1] 298722 0
129 Glen Osmond Road
Eastwood SA 5063
Ethics committee country [1] 298722 0
Australia
Date submitted for ethics approval [1] 298722 0
20/09/2017
Approval date [1] 298722 0
23/10/2017
Ethics approval number [1] 298722 0

Summary
Brief summary
This is a single-centre, randomised, open-label, two-way crossover, single dose study with three treatment periods conducted in healthy participants. The study is designed to compare the PK profiles of a single oral dose of an immediate and extended release formulation of propagermanium, and to identify if there is a food-effect on the extended release formulation. Participants who meet all inclusion and none of the exclusion criteria will be evaluated throughout the study. In addition to PK assessments, safety and tolerability data will be collected during the course of the study.
Approximately 14 participants will be enrolled into two cohorts (Cohort A and Cohort B). Participants in Cohort A will receive the immediate release (IR) formulation while fasting at Dose 1, the extended release (ER) formulation while fasting at Dose 2, and the ER formulation after a meal at Dose 3. Participants in Cohort B will receive the ER formulation while fasting at Dose 1, the IR formulation while fasting at Dose 2, and the ER formulation after a meal at Dose 3. No participant will be a member of more than one cohort.
Participants will be screened from -14 days prior to dose administration. Participants will be admitted to the unit on Day -1 and will remain confined to the unit for 24 hours post-dose. On Day 1, participants will receive Dose 1 and will complete procedures as detailed in Table 3. On Days 7 and 14 participants will return to the unit and will receive Doses 2 and 3 on Days 8 and 15, respectively and will complete procedures as detailed in Table 3. Participants will return to the clinic on Day 24 for follow-up visits.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 65846 0
Dr Peter Schrader
Address 65846 0
C/- Linear Clinical Research
Level 1 B Block, QEII Medical Centre, Hospital Avenue,
Nedlands, Western Australia, 6009, Australia
Country 65846 0
Australia
Phone 65846 0
+61 8 6382 5100
Fax 65846 0
Email 65846 0
pschrader@linear.org.au
Contact person for public queries
Name 65847 0
Ms Nicola Norton
Address 65847 0
Linear Clinical Research
Level 1 B Block, QEII Medical Centre, Hospital Avenue,
Nedlands, Western Australia, 6009, Australia
Country 65847 0
Australia
Phone 65847 0
+61 8 6382 5116
Fax 65847 0
Email 65847 0
nnorton@linear.org.au
Contact person for scientific queries
Name 65848 0
Dr Peter Schrader
Address 65848 0
Linear Clinical Research
Level 1 B Block, QEII Medical Centre, Hospital Avenue,
Nedlands, Western Australia, 6009, Australia
Country 65848 0
Australia
Phone 65848 0
+61 8 6382 5100
Fax 65848 0
Email 65848 0
pschrader@linear.org.au

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary